Cargando…

Besifloxacin: Efficacy and Safety in Treatment and Prevention of Ocular Bacterial Infections

This comprehensive review summarizes the mechanism of action, pharmacokinetics, efficacy, and safety of besifloxacin ophthalmic suspension, 0.6% and examines its role in the treatment of ocular surface bacterial infections. Besifloxacin possesses balanced activity against bacterial topoisomerase II...

Descripción completa

Detalles Bibliográficos
Autores principales: Mah, Francis S., Sanfilippo, Christine M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909673/
https://www.ncbi.nlm.nih.gov/pubmed/27010720
http://dx.doi.org/10.1007/s40123-016-0046-6
_version_ 1782437857156136960
author Mah, Francis S.
Sanfilippo, Christine M.
author_facet Mah, Francis S.
Sanfilippo, Christine M.
author_sort Mah, Francis S.
collection PubMed
description This comprehensive review summarizes the mechanism of action, pharmacokinetics, efficacy, and safety of besifloxacin ophthalmic suspension, 0.6% and examines its role in the treatment of ocular surface bacterial infections. Besifloxacin possesses balanced activity against bacterial topoisomerase II (also called DNA gyrase) and topoisomerase IV. It has shown a low potential to select for bacterial resistance in vitro and demonstrated strong in vitro activity against many Gram-positive, Gram-negative, and anaerobic organisms, including methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis (MRSA and MRSE, respectively). Ocular pharmacokinetic studies have shown that besifloxacin achieves high, sustained concentrations in the tear fluid and conjunctiva following topical administration, with negligible systemic exposure. Large randomized, controlled clinical trials have established the efficacy and safety of besifloxacin administered three times daily for 5 days for treatment of acute bacterial conjunctivitis in both adults and children, with high rates of clinical resolution (up to more than 70% by day 5) and bacterial eradication (more than 90% by day 5), and a low incidence of adverse events. Additionally, besifloxacin applied twice daily for 3 days demonstrated greater efficacy than vehicle in treating bacterial conjunctivitis. Case reports, a large retrospective chart review, and animal studies have provided supporting evidence for the efficacy of besifloxacin in the management of acute bacterial keratitis. There is some evidence to suggest that besifloxacin may provide an advantage over other current-generation fluoroquinolones in antimicrobial prophylaxis for ocular surgery. Besifloxacin is an appropriate option for treatment of bacterial conjunctivitis, and its use in the treatment of bacterial keratitis and lid disorders, as well as for surgical prophylaxis, appears promising and warrants further evaluation.
format Online
Article
Text
id pubmed-4909673
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-49096732016-07-01 Besifloxacin: Efficacy and Safety in Treatment and Prevention of Ocular Bacterial Infections Mah, Francis S. Sanfilippo, Christine M. Ophthalmol Ther Review This comprehensive review summarizes the mechanism of action, pharmacokinetics, efficacy, and safety of besifloxacin ophthalmic suspension, 0.6% and examines its role in the treatment of ocular surface bacterial infections. Besifloxacin possesses balanced activity against bacterial topoisomerase II (also called DNA gyrase) and topoisomerase IV. It has shown a low potential to select for bacterial resistance in vitro and demonstrated strong in vitro activity against many Gram-positive, Gram-negative, and anaerobic organisms, including methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis (MRSA and MRSE, respectively). Ocular pharmacokinetic studies have shown that besifloxacin achieves high, sustained concentrations in the tear fluid and conjunctiva following topical administration, with negligible systemic exposure. Large randomized, controlled clinical trials have established the efficacy and safety of besifloxacin administered three times daily for 5 days for treatment of acute bacterial conjunctivitis in both adults and children, with high rates of clinical resolution (up to more than 70% by day 5) and bacterial eradication (more than 90% by day 5), and a low incidence of adverse events. Additionally, besifloxacin applied twice daily for 3 days demonstrated greater efficacy than vehicle in treating bacterial conjunctivitis. Case reports, a large retrospective chart review, and animal studies have provided supporting evidence for the efficacy of besifloxacin in the management of acute bacterial keratitis. There is some evidence to suggest that besifloxacin may provide an advantage over other current-generation fluoroquinolones in antimicrobial prophylaxis for ocular surgery. Besifloxacin is an appropriate option for treatment of bacterial conjunctivitis, and its use in the treatment of bacterial keratitis and lid disorders, as well as for surgical prophylaxis, appears promising and warrants further evaluation. Springer Healthcare 2016-03-24 2016-06 /pmc/articles/PMC4909673/ /pubmed/27010720 http://dx.doi.org/10.1007/s40123-016-0046-6 Text en © The Author(s) 2016 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Mah, Francis S.
Sanfilippo, Christine M.
Besifloxacin: Efficacy and Safety in Treatment and Prevention of Ocular Bacterial Infections
title Besifloxacin: Efficacy and Safety in Treatment and Prevention of Ocular Bacterial Infections
title_full Besifloxacin: Efficacy and Safety in Treatment and Prevention of Ocular Bacterial Infections
title_fullStr Besifloxacin: Efficacy and Safety in Treatment and Prevention of Ocular Bacterial Infections
title_full_unstemmed Besifloxacin: Efficacy and Safety in Treatment and Prevention of Ocular Bacterial Infections
title_short Besifloxacin: Efficacy and Safety in Treatment and Prevention of Ocular Bacterial Infections
title_sort besifloxacin: efficacy and safety in treatment and prevention of ocular bacterial infections
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909673/
https://www.ncbi.nlm.nih.gov/pubmed/27010720
http://dx.doi.org/10.1007/s40123-016-0046-6
work_keys_str_mv AT mahfranciss besifloxacinefficacyandsafetyintreatmentandpreventionofocularbacterialinfections
AT sanfilippochristinem besifloxacinefficacyandsafetyintreatmentandpreventionofocularbacterialinfections